OPRX
OptimizeRx Corp.
$6.66
Platform & Compounding FCF
85%
Two-stage FCF DCF
Strong
·
Conviction
Undervalued
Trading 87.7% below fair value
You pay
$6.66
Bear
$21.99
Fair
$53.95
Bull
$78.49
Bear
$21.99
+230.1%
18% stage 1 growth, 11% discount
Fair
$53.95
+710.0%
30% stage 1 growth, 11% discount
Bull
$78.49
+1078.5%
35% stage 1 growth, 11% discount
Key Value Driver
FCF growth rate (30% base case)
Terminal Value % of EV
52%
Implied Market Multiple
9.5x
Market is pricing in (growth)
-1.3%
vs 29.9% base
Summary
Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $10.50 from 15 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $53.95 per share.
Warnings
Stock-based employee pay equals 136% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $10.50 (from 15 analysts). Our estimate is 552% above the consensus -- consider that gap carefully.
Key Risks
- P/E alone misleads — earnings depressed by growth investment
- Cyclical or commodity businesses may be misclassified as platforms
- Terminal value dominance suggests sensitivity to long-run assumptions